Viracta Therapeutics, Inc.: Nasdaq/NYSE listing notice — Viracta Therapeutics to be delisted from Nasdaq effective Feb 4, 2025; expects OTC Pink listing under VIRX

Viracta Therapeutics, Inc.

Received Nasdaq delisting notice on Jan 31, 2025; trading suspended at open on Feb 4, 2025.
Failed minimum bid price ($1.00) and stockholders' equity ($2.5M) continued listing requirements.
Expects common stock to trade on OTC Pink Open Market under symbol VIRX; warns of reduced liquidity.
No assurance of continued trading or sufficient volume on OTC Pink market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Viracta Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5450(a)(1), 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5450(a)(1), 5550(b)(1)

Exact text from the filing

January 31, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock will be delisted from Nasdaq and trading in the Company’s s

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Viracta Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5450(a)(1), 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5450(a)(1), 5550(b)(1)

Exact text from the filing

January 31, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock will be delisted from Nasdaq and trading in the Company’s shares will be suspended at the open of trading on February 4, 2025. As previously reported, on May 28, 2024, the Company received a notification from the Listing Qualifications Staff of Nasdaq notifying the Company that it no longer complied with the $1.00 per share minimum requirement for continued listing under Nasdaq Listing Rule 5450(a)(1). Also as previously reported, on N

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Viracta Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

January 31, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock will be delisted from Nasdaq and trading in the Company’s shares will be suspended at the open of trading on February 4, 2025. As previously reported, on May 28, 2024, the Company received a notification from the Listing Qualifications Staff of Nasdaq notifying the Company that it no longer complied with the $1.00 per share minimum requirement for continued listing under Nasdaq Listing Rule 5450(a)(1). Also as previously reported, on N

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-25-011792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.